Literature DB >> 28546220

Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.

Lei Sun1, Xiaoxiao Yang1, Qi Li1, Peng Zeng1, Ying Liu1, Lipei Liu1, Yuanli Chen1, Miao Yu1, Chuanrui Ma1, Xiaoju Li1, Yan Li1, Rongxin Zhang1, Yan Zhu1, Qing Robert Miao1, Jihong Han2, Yajun Duan2.   

Abstract

OBJECTIVE: The reduced adiponectin levels are associated with atherosclerosis. Adiponectin exerts its functions by activating adiponectin receptor (AdipoR). Proprotein convertase subtilisin kexin type 9 (PCSK9) degrades LDLR protein (low-density lipoprotein receptor) to increase serum LDL-cholesterol levels. PCSK9 expression can be regulated by PPARγ (peroxisome proliferator-activated receptor γ) or SREBP2 (sterol regulatory element-binding protein 2). The effects of AdipoR agonists on PCSK9 and LDLR expression, serum lipid profiles, and atherosclerosis remain unknown. APPROACH AND
RESULTS: At cellular levels, AdipoR agonists (ADP355 and AdipoRon) induced PCSK9 transcription/expression that solely depended on activation of PPAR-responsive element in the PCSK9 promoter. AdipoR agonists induced PPARγ expression; thus, the AdipoR agonist-activated PCSK9 expression/production was impaired in PPARγ deficient hepatocytes. Meanwhile, AdipoR agonists transcriptionally activated LDLR expression by activating SRE in the LDLR promoter. Moreover, AMP-activated protein kinase α (AMPKα) was involved in AdipoR agonist-activated PCSK9 expression. In wild-type mice, ADP355 increased PCSK9 and LDLR expression and serum PCSK9 levels, which was associated with activation of PPARγ, AMPKα and SREBP2 and reduction of LDL-cholesterol levels. In contrast, ADP355 reduced PCSK9 expression/secretion in apoE-deficient (apoE-/-) mice, but it still activated hepatic LDLR, PPARγ, AMPKα, and SREBP2. More importantly, ADP355 inhibited lesions in en face aortas and sinus lesions in aortic root in apoE-/- mice with amelioration of lipid profiles.
CONCLUSIONS: Our study demonstrates that AdipoR activation by agonists regulated PCSK9 expression differently in wild-type and apoE-/- mice. However, ADP355 activated hepatic LDLR expression and ameliorated lipid metabolism in both types of mice and inhibited atherosclerosis in apoE-/- mice.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  AMP-activated protein kinases; adiponectin; adiponectin receptors; atherosclerosis; peroxisome proliferator-activated receptors

Mesh:

Substances:

Year:  2017        PMID: 28546220     DOI: 10.1161/ATVBAHA.117.309630

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  20 in total

1.  Updates on Approaches for Studying Atherosclerosis.

Authors:  Congqing Wu; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

2.  Reporting Sex and Sex Differences in Preclinical Studies.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

Review 3.  Emerging Roles for Adipose Tissue in Cardiovascular Disease.

Authors:  Elizabeth E Ha; Robert C Bauer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

4.  Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.

Authors:  Dandan Wang; Xiaoxiao Yang; Yuanli Chen; Ke Gong; Maoyun Yu; Yongyao Gao; Ximei Wu; Huaqing Hu; Chenzhong Liao; Jihong Han; Yajun Duan
Journal:  J Biol Chem       Date:  2020-09-10       Impact factor: 5.157

5.  TL1A inhibits atherosclerosis in apoE-deficient mice by regulating the phenotype of vascular smooth muscle cells.

Authors:  Dan Zhao; Jiaqi Li; Chao Xue; Ke Feng; Lipei Liu; Peng Zeng; Xiaolin Wang; Yuanli Chen; Luyuan Li; Zhisong Zhang; Yajun Duan; Jihong Han; Xiaoxiao Yang
Journal:  J Biol Chem       Date:  2020-09-22       Impact factor: 5.157

6.  Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9.

Authors:  I-Chih Chen; Wei-Kung Tseng; Yi-Heng Li; Shih-Ya Tseng; Ping-Yen Liu; Ting-Hsing Chao
Journal:  Oncotarget       Date:  2017-11-14

7.  Isoquinoline Alkaloids and Indole Alkaloids Attenuate Aortic Atherosclerosis in Apolipoprotein E Deficient Mice: A Systematic Review and Meta-Analysis.

Authors:  Yibing Zhang; Min Li; Xiangjun Li; Tong Zhang; Meng Qin; Liqun Ren
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

Review 8.  Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein-Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?

Authors:  Julita Anna Krahel; Anna Baran; Tomasz W Kamiński; Iwona Flisiak
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

9.  Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data.

Authors:  Julita Anna Krahel; Anna Baran; Tomasz W Kamiński; Magdalena Maciaszek; Iwona Flisiak
Journal:  J Clin Med       Date:  2020-03-26       Impact factor: 4.241

10.  Discovery of a novel potent peptide agonist to adiponectin receptor 1.

Authors:  Sunghwan Kim; Younho Lee; Jun Woo Kim; Young-Jin Son; Min Jung Ma; Jee-Hyun Um; Nam Doo Kim; Sang Hyun Min; Dong Il Kim; Brian B Kim
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.